Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
May 09, 2024
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
May 06, 2024
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
Apr 29, 2024
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Apr 25, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Apr 18, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Apr 11, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Apr 10, 2024
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Apr 02, 2024
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Mar 28, 2024
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Mar 26, 2024
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
1
2
3
4
5
6
<<
<
>
>>
Privacy